The report features an extensive study of the currentmarket landscape and future opportunities associated with the contractmanufacturing of HPAPIs and cytotoxic drugs. The study also features a detailedanalysis of the key drivers and trends related to this evolving domain. Inaddition to other elements, the study includes:
§ A detailed assessment of the current market landscape of companiesoffering contract services for manufacturing HPAPIs and cytotoxic drugs.
§ A competitiveness analysis of HPAPI and cytotoxic drugscontract manufacturers, featuring insightful representations.
§ Detailed profiles of leading contract manufacturers ofHPAPI and cytotoxic drugs (shortlisted on the basis of proprietarycriterion).
§ An analysis of the partnerships that have been establishedin this domain, in the recent past.
§ An analysis of the various expansion initiatives undertakenby the players in this domain.
§ An estimate of the overall, installed capacity formanufacturing HPAPIs and cytotoxic drugs based on data reported by industrystakeholders in the public domain.
§ A qualitative analysis to decide whether to manufacture thepotent products in-house or engage the services of a CMO.
§ A discussion on affiliated trends, key drivers andchallenges which are likely to impact the industry’s evolution.
§ A case study on the antibody drug conjugates (ADCs)manufacturing market, highlighting a list of contract service providers andin-house manufacturers in this domain.
§ A detailed market forecast, featuring analysis of thecurrent and projected future opportunity across key market segments (listedbelow)
§ Typeof Product
§ HPAPIs
§ HighlyPotent Finished Dosage Forms
§ Company Size
§ Small-sized
§ Mid-sized
§ Large / Very Large
§ Scaleof Operation
§ Preclinical / Clinical
§ Commercial
§ Typeof Pharmacological Molecule
§ Small Molecules
§ Biologics
§ Typeof Highly Potent Finished Dosage Form
§ Injectables
§ OralSolids
§ Creams
§ Others
§ Keygeographical regions
§ NorthAmerica
§ Europe
§ AsiaPacific
§ Restof the World
The report includes detailed transcripts of discussionsheld with the following senior level representatives of stakeholder companies:
§ Antonella Mancuso (Vice President and Chief OperatingOfficer, BSP Pharmaceuticals) and Maria Elena Guadagno (Business Director, BSPPharmaceuticals)
§ Klaus Hellerbrand (Managing Director, ProJect Pharmaceutics)
§ Kevin Rosenthal (Business Head, Formulations and FinishedProducts, Alphora Research)
§ Jennifer L Mitcham (Director, Business Development,Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, CatalentPharma Solutions)
§ Roberto Margarita (Business Development Director,CordenPharma)
§ Allison Vavala (Senior Manager, Business Development,Helsinn)
§ Mark Wright (Site Head, Piramal Healthcare)
§ Javier E. Aznárez Araiz (Business Development Technician,Idifarma)
Keycompanies covered in the report
§ AbbVie Contract Manufacturing
§ CARBOGEN AMCIS
§ Catalent
§ Evonik
§ Formosa Laboratories
§ Intas
§ Lonza
§ MabPlex
§ Pfizer CentreOne
Formore information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html
Other Recent Offerings
1. Antibody ContractManufacturing Market,2020 – 2030
2. Cell TherapyManufacturing Market(3rd Edition), 2019 – 2030
3. Biopharma ContractManufacturing Market(3rd Edition), 2019 – 2030
About Roots Analysis
Roots Analysis is one of the fastest growing marketresearch companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
